Maze Therapeutics director gifts 7,422 shares

Maze Therapeutics, Inc. director Charles J. Homcy reported a bona fide gift transfer of 7,422 shares of common stock on May 4, 2026.

Accepted by SEC EDGAR 05/06/2026 - 04:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director Charles J. Homcy reported a bona fide gift transfer of 7,422 shares of common stock on May 4, 2026. The gift was made for no consideration and is described as exempt under Rule 16b-5. After the transaction, Homcy directly holds 31,113 shares of Maze Therapeutics common stock, a total that includes shares previously held by the Charles J. Homcy Revocable Trust UA 11/4/1998.

Insider Trade Summary

7,422 shares gifted

Gift 1 txn

Insider HOMCY CHARLES J

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock	7,422	$0.00	$0.00

Holdings After Transaction: Common Stock — 31,113 shares (Direct)

Footnotes (2)

1. F1. The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5.
2. F2. The total reflected in Column 5 of Table I includes shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998.

Key Figures

Shares gifted: 7,422 shares Shares held after transaction: 31,113 shares Reported gift price: $0.0000 per share +2 more

5 metrics

Shares gifted 7,422 shares Bona fide gift of Maze Therapeutics common stock on May 4, 2026

Shares held after transaction 31,113 shares Direct Maze Therapeutics common stock holdings following the gift

Reported gift price $0.0000 per share Indicates no consideration for the bona fide gift transfer

Gift transactions count 1 transaction Single bona fide gift reported in this Form 4

Gifted share total in summary 7,422 shares GiftShares in transaction summary for Maze Therapeutics common stock

Key Terms

bona fide gift, Rule 16b-5, Revocable Trust, Column 5 of Table I

4 terms

bona fide gift financial

"The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5."

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Rule 16b-5 regulatory

"The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5."

Revocable Trust financial

"shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Column 5 of Table I regulatory

"The total reflected in Column 5 of Table I includes shares which were previously held directly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Maze Therapeutics (MAZE) disclose in this Form 4?

Maze Therapeutics director Charles J. Homcy reported a bona fide gift of 7,422 shares of common stock. This was a non-cash transfer made for no consideration and classified as exempt under Rule 16b-5, rather than an open-market sale or purchase.

How many Maze Therapeutics (MAZE) shares did Charles Homcy gift?

Charles J. Homcy gifted 7,422 shares of Maze Therapeutics common stock. The Form 4 identifies the transaction as a bona fide gift, meaning the shares were transferred without payment, and it is treated as an exempt disposition under applicable insider trading rules.

At what price were the gifted Maze Therapeutics (MAZE) shares transferred?

The gifted Maze Therapeutics shares were transferred at a reported price of $0.0000 per share. This reflects that the transaction was a bona fide gift made for no consideration, not a market sale, and therefore did not generate any cash proceeds for the reporting person.

How many Maze Therapeutics (MAZE) shares does Charles Homcy hold after the gift?

After the gift transaction, Charles J. Homcy holds 31,113 shares of Maze Therapeutics common stock directly. The filing notes this total includes shares that were previously held by the Charles J. Homcy Revocable Trust UA 11/4/1998 and are now reflected in his direct ownership.

Was the Maze Therapeutics (MAZE) Form 4 transaction a sale on the open market?

No, the Form 4 transaction was not an open-market sale. It is explicitly described as a bona fide gift of 7,422 shares for no consideration, exempt under Rule 16b-5, which means no sale price or trading proceeds were involved in this disposition.

What regulatory exemption applies to Charles Homcy’s Maze Therapeutics (MAZE) gift?

The gift is reported as exempt under Rule 16b-5. This rule allows certain transactions, such as bona fide gifts made for no consideration, to be treated as exempt from short-swing profit rules that normally apply to insider purchases and sales within a six-month period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		G(1)		7,422	D	$0	31,113(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5.

2. The total reflected in Column 5 of Table I includes shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998.

	/s/ Courtney Phillips, as attorney-in-fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)